Physician profile
Abdullah Abu Kar
NPI 1407239718
$1,723.58
in general payments reported to CMS, 2019-2025
16 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $198 · 2021: $125 · 2022: $290 · 2024: $668 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $332.36 | 2024 | Assure Wcd |
| Abbott Laboratories | $165.90 | 2025 | Perclose Prostyle |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.78 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $147.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $127.66 | 2024 | |
| Janssen Biotech, INC. | $124.99 | 2022 | |
| Vifor Pharma, INC. | $124.97 | 2020 | |
| Alexion Pharmaceuticals, INC. | $124.97 | 2021 | |
| Eisai INC. | $121.90 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.99 | 2024 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $72.80 | 2020 | |
| Allergan, INC. | $40.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.64 | 2019 | |
| Pfizer INC. | $22.73 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Abu Kar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.